Diagnostic Capacity of RASSF1A Promoter Methylation as a Biomarker in Tissue, Brushing, and Blood Samples of Nasopharyngeal Carcinoma

Meng, Yijun; Huang, Tao; Yang, Ping; Chen, Si

doi:10.1016/j.ebiom.2017.03.038

Cited by 44 publications

(32 citation statements)

References 45 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Screening for HNSCC depends on clinical symptoms and imaging examinations (laryngoscopy, computed tomography, magnetic resonance imaging, and positron emission tomography) and histopathological examination; however, owing to the non‐specificity of symptoms in early‐stage disease and ineffective conventional cancer‐related biomarkers, the early detection of HNSCC remains unsatisfactory. As they occur early in carcinogenesis and have other advantageous characteristics, abnormal methylation patterns represent potential markers for early detection of cancer and can even be non‐invasively detected in various body fluids (blood, bronchial aspirates, brushing, saliva, and urine) . In the present study, we constructed ROC curves and calculated the AUC to determine the diagnostic value of HOXA9 methylation for HNSCC.…”

Section: Discussionmentioning

confidence: 99%

The clinical significance of HOXA9 promoter hypermethylation in head and neck squamous cell carcinoma

Zhou

et al. 2019

Clinical Laboratory Analysis

View full text Add to dashboard Cite

BackgroundThe purpose of the current study was to assess the association between HOXA9 (homeobox A9) promoter methylation and head and neck squamous cell carcinoma (HNSCC) and its diagnostic value.MethodsQuantitative methylation‐specific PCR (qMSP) was applied to measure HOXA9 promoter methylation levels in 145 paired HNSCC and corresponding normal tissue samples. Data from the Cancer Genome Atlas (TCGA) database (n = 578; 528 HNSCC and 50 normal) were also analyzed.ResultsSignificantly higher levels of HOXA9 promoter methylation were detected in HNSCC, compared with normal, tissues (our cohort: P = 1.06E‐35; TCGA cohort: P = 3.06E‐39). Moreover, HOXA9 methylation was significantly increased in patients with advanced tumor (T) stage, lymph node metastasis, and advanced clinical stage. Areas under the receiver characteristic curves (AUCs) based on our cohort and TCGA data were 0.930 and 0.967, respectively.ConclusionIn summary, our study reveals that HOXA9 promoter hypermethylation contributes to the risk of HNSCC and its progression and metastasis. Additionally, HOXA9 hypermethylation is a potential biomarker for the early diagnosis and screening of patients with HNSCC.

show abstract

Section: Discussionmentioning

confidence: 99%

The clinical significance of HOXA9 promoter hypermethylation in head and neck squamous cell carcinoma

Zhou

et al. 2019

Clinical Laboratory Analysis

View full text Add to dashboard Cite

show abstract

“…Interestingly, the AUC was 0.95 and revealed efficient diagnostic power of CDKN2A promoter methylation in diagnosis of HNSCCs from precancerous samples, which can reveal that methylation is a relatively early molecular change during carcinogenesis as previous study concluded [13,104]. Some studies have suggested that DNA methylation can be detected in body fluid samples (blood, bronchial aspirates, brushing, saliva, and urine) as a noninvasive molecular biomarker for cancer screening and diagnosis [105][106][107]. We conducted a subgroup analysis based on sample type and the results showed that the AUC of saliva was 0.96, which was greater than that of tissue.…”

Section: Discussionmentioning

confidence: 76%

The Association and Clinical Significance of CDKN2A Promoter Methylation in Head and Neck Squamous Cell Carcinoma: a Meta-Analysis

Zhou

Shen

et al. 2018

Cell Physiol Biochem

View full text Add to dashboard Cite

Background/Aims: The association between cyclin-dependent kinase inhibitor 2A (CDKN2A) hypermethylation and head and neck squamous cell carcinoma (HNSCC) risk has been investigated by a number of studies. However, these studies have not demonstrated consistent results. Moreover, the role of CDKN2A methylation in HNSCC carcinogenesis and its clinical significance remain unclear. Methods: We performed a systematic meta-analysis based on 72 articles (including 3399 HNSCCs, 668 premalignant lesions, and 2393 normal controls) from the PubMed, Google Scholar, Web of Science, Embase, China National Knowledge Infrastructure and Wanfang databases. Results: Our study showed a significant increase in the frequency of CDKN2A methylation during HNSCC carcinogenesis (HNSCC vs. normal controls, odds ratio (OR) = 6.72, P < 0.01; HNSCC vs. precancerous lesions, OR = 1.89, P < 0.05; precancerous lesions vs. normal controls, OR = 14.70, P < 0.01). Moreover, CDKN2A methylation was significantly associated with gender (OR = 1.34; P < 0.05) and lymph node metastasis (OR = 2.32; P < 0.01). The area under summary receiver operating characteristic curve (AUC) for diagnosis of HNSCC based on all samples and saliva sample subgroup were 0.77 and 0.96, respectively. Additionally, CDKN2A hypermethylation was significantly associated with shorter overall survival (OS) (hazard ratio (HR) = 1.01, P < 0.05) and recurrence-free survival (RFS) (HR = 1.77, P < 0.05). Conclusion: Our findings indicate CDKN2A methylation is involved in the carcinogenesis, progression, and metastasis of HNSCC. Furthermore, methylated CDKN2A could be a potential diagnostic and prognostic biomarker for HNSCC.

show abstract

“…Some studies suggested DNA methylation as a promising tool for the diagnosis of cancer [88-91]. We analyzed the diagnostic effect of MLH1 promoter methylation in GC for the results with significant OR values and found that MLH1 promoter methylation could not distinguish GC from adjacent tissues, gastric adenomas, chronic gastritis, normal gastric mucosa, or normal healthy blood samples (i.e., the poor sensitivity value of < 0.5).…”

Section: Discussionmentioning

confidence: 99%

Epigenetic Silencing of the MLH1 Promoter in Relation to the Development of Gastric Cancer and its use as a Biomarker for Patients with Microsatellite Instability: a Systematic Analysis

Hu¹,

Qin²,

Zhang³

et al. 2018

Cell Physiol Biochem

Self Cite

View full text Add to dashboard Cite

Background/Aims: Human mutL homolog 1 (MLH1) promoter methylation was reported in gastric cancer (GC). This study determined the clinicopathological, prognostic, and diagnostic effects of MLH1 promoter methylation in GC. Methods: The combined odds ratio (OR) or hazard ratio (HR) and their corresponding 95% confidence intervals (95% CI) were calculated. The pooled sensitivity, specificity, and area under the curve (AUC) were analyzed. Results: A total of 4654 GC patients and 3669 non-malignant controls were identified in this systematic analysis. MLH1 promoter methylation was significantly higher in GC samples than in gastric adenomas, chronic gastritis, adjacent tissues, normal gastric mucosa, and normal healthy blood samples, but it exhibited a similar frequency in GC vs. intestinal metaplasia and dysplasia samples. MLH1 promoter methylation correlated with age and microsatellite instability (MSI), but it was not associated with gender, H. pylori infection, smoking, drinking behaviors, pathological histology, tumor differentiation, clinical stage, lymph node status, distant metastasis, or overall survival of GC. MLH1 promoter methylation exhibited a poor sensitivity value (< 0.5) in patients with GC compared with adjacent tissues, gastric adenomas, chronic gastritis, normal gastric mucosa, and normal healthy blood samples. The pooled sensitivity, specificity, and AUC of MLH1 promoter methylation in GC with MSI vs. GC with microsatellite stability (MSS) samples were 0.64, 0.96, and 0.90, respectively. Conclusions: Our results suggest that the detection of MLH1 promoter methylation may be a potential prognostic biomarker for GC patients with MSI.

show abstract

Diagnostic Capacity of RASSF1A Promoter Methylation as a Biomarker in Tissue, Brushing, and Blood Samples of Nasopharyngeal Carcinoma

Cited by 44 publications

References 45 publications

The clinical significance of HOXA9 promoter hypermethylation in head and neck squamous cell carcinoma

The clinical significance of HOXA9 promoter hypermethylation in head and neck squamous cell carcinoma

The Association and Clinical Significance of CDKN2A Promoter Methylation in Head and Neck Squamous Cell Carcinoma: a Meta-Analysis

Epigenetic Silencing of the MLH1 Promoter in Relation to the Development of Gastric Cancer and its use as a Biomarker for Patients with Microsatellite Instability: a Systematic Analysis

Contact Info

Product

Resources

About